Role of AI in CE for the Identification of SB Lesions in Patients With Small Intestinal Bleeding.
NCT ID: NCT04821349
Last Updated: 2024-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
137 participants
INTERVENTIONAL
2021-02-16
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Robot Assisted Magnetically Controlled Capsule Endoscopy in Patients With Iron Deficiency Anaemia
NCT07197424
Real-Time Identification System of Magnetically Controlled Capsule Endoscopy Using Artificial Intelligence
NCT04203264
Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel
NCT05949268
Emergency Capsule Endoscopy in Severe GI-bleeding
NCT01584869
Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel
NCT01441219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* after negative upper and lower endoscopy
* France: after negative pregnancy test
* Hb cut-off male: \<13, female: \<12 Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient, as specified below.1. Regimen of preparation AI depends on the possibility of the software to "see" images. An inadequate cleansing level precludes a proper visualization and the impact of technology. In order to have homogenous results, a standard regimen of preparation is advisable. The regimen includes a split dose of PEG-based solution (PlenVu, Moviprep) as recommended by ESGE guideline - technical report. Dose 1 will be administered at 7 pm of the day before and dose 2 in the morning of the procedure in order to be completed at least 1 hour before capsule ingestion. On the day before patients can have breakfast and a light meal. After lunch they should be fasting. Two and 4 hours after capsule ingestion patient are allowed to drink clear liquids and a light meal, respectively.
2\. Standard reading Each center will review the images collected according to the "normal reading" as recommended by ESGE guidelines. To compare reading time correctly, readers must read the video without including annotation of images. All lesions should be considered independently of their relevance. Findings are not marked on every image if they appear repeatedly on every consecutive image, but if they appear repeatedly with normal images in between. Annotations should be done after the reading, each lesion shall be labelled if it belongs to P1/2 category according to the Saurin Classification. Definition of P1, P2: red spots on the intestinal mucosa or small or isolated erosions or angioectasia, ulcers, tumors or varices or any other bleeding abnormality.
3\. AI-assisted reading Each center will receive from another center anonymized patient videos that have been uploaded on an encrypted USB key. Indeed, expert gastroenterologists from each center will proceed with AI-assisted video reading without knowing which center the video comes from nor the results of the normal reading. Reading conditions are the same as for standard reading.
4\. Consensus reading Results from both normal and AI-assisted reading will be compared. In the case of significant disagreement between the results from conventional capsule endoscopy reading and AI-assisted reading (e.g. missed lesions), a consensus review for each center will be done. Any lesion shall be considered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Results from both normal and AI-assisted reading will be compared. In the case of significant disagreement between the results from conventional capsule endoscopy reading and AI-assisted reading (e.g. missed lesions), a consensus review for each center will be done. Any lesion shall be considered.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm study
Standard reading Group vs AI-assisted reading Group
Capsule endoscopy
A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.
Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capsule endoscopy
A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.
Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known or suspected intestinal obstruction
* Non-steroidal anti-inflammatory drugs (twice weekly or more) during the 4 weeks preceding enrollment
* Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule
* Patient with known gastrointestinal motility disorders
* Subjects with known or suspected delayed gastric emptying
* Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions
* Patient has any allergy or other known contraindication or intolerance to the medications used in the study
* Patient has any condition, which precludes compliance with study and/or device instructions
* Patient with any contraindication to take the bowel preparation product
* Women who are either pregnant or nursing at the time of screening, or are of child- bearing potential and do not practice medically acceptable methods of contraception
* Concurrent participation in another clinical trial using any investigational drug or device
* Patient suffers from a life-threatening condition
* Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters
* Patients with pace-maker or implantable cardioverter
* Patient did not sign informed consent
* Endoscopic placement of the capsule
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humanitas Hospital, Italy
OTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Skane University Hospital
OTHER
Hospital Clinic of Barcelona
OTHER
Universitätsklinikum Hamburg-Eppendorf
OTHER
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER
Endo-Kapszula Magánorvosi Centrum
UNKNOWN
Szeged University
OTHER
Saint Antoine University Hospital
OTHER
Hospital Avicenne
OTHER
South Tyneside and Sunderland NHS Foundation Trust
OTHER
Northwick Park Hospital
OTHER
Hospices Civils de Lyon
OTHER
Royal Free Hospital NHS Foundation Trust
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Fondazione Poliambulanza Istituto Ospedaliero
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Poliambulanza
Brescia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spada C, Piccirelli S, Hassan C, Ferrari C, Toth E, Gonzalez-Suarez B, Keuchel M, McAlindon M, Finta A, Rosztoczy A, Dray X, Salvi D, Riccioni ME, Benamouzig R, Chattree A, Humphries A, Saurin JC, Despott EJ, Murino A, Johansson GW, Giordano A, Baltes P, Sidhu R, Szalai M, Helle K, Nemeth A, Nowak T, Lin R, Costamagna G. AI-assisted capsule endoscopy reading in suspected small bowel bleeding: a multicentre prospective study. Lancet Digit Health. 2024 May;6(5):e345-e353. doi: 10.1016/S2589-7500(24)00048-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ArtiC STUDY-NP4350 v.05 140920
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.